Product Description
Mechanisms of Action: IAP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Breakthrough Therapy - Head and Neck Cancer *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Debiopharm International
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Canada, China, France, Germany, Ireland, Italy, Netherlands, Norway, Poland, Romania, Slovenia, Spain, United Kingdom, United States
Active Clinical Trial Count: 11
Highest Development Phases
Phase 3: Head and Neck Cancer|Squamous Cell Carcinoma
Phase 2: Breast Cancer|Cervical Cancer|Colorectal Cancer|Endometrial Cancer|Gastrointestinal Cancer|Oncology Solid Tumor Unspecified|Ovarian Cancer|Peritoneal Cancer|Small Cell Lung Cancer
Phase 1: Adenocarcinoma|Glioma|Healthy Volunteers|Non-Small-Cell Lung Cancer|Pancreatic Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Phase III xevinapant and radiotherapy in resected LA SCCHN | P3 |
Active, not recruiting |
Head and Neck Cancer|Squamous Cell Carcinoma |
2030-05-25 |
|
| RAVINA | P2 |
Suspended |
Head and Neck Cancer|Squamous Cell Carcinoma |
2029-07-01 |
|
| IRB23-0294 | P1 |
Active, not recruiting |
Squamous Cell Carcinoma|Head and Neck Cancer |
2027-10-01 |
|
| TrilynX | P3 |
Active, not recruiting |
Squamous Cell Carcinoma|Head and Neck Cancer |
2027-06-23 |